Figure 4.
Diagnostic performance of EUS-FNA, CA19-9, ctDNA, and FNA specimen KRAS mutation detection either alone or in combination for distinguishing patients with pancreatic cancer (n = 105) from control patients (n = 44). KRAS mutation was determined using ddPCR. ROC curves: X-axis, 1-specificity; Y-axis, sensitivity. CA19-9, carbohydrate antigen 19-9; ctDNA, circulating tumor DNA; ddPCR, digital droplet PCR; EUS-FNA, endoscopic ultrasound-guided fine-needle aspiration; AUC, area under the curve.